Moleculin Biotech, Inc. (MBRX) Completes Part A Enrollment in Pivotal AML Trial

Moleculin Biotech completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial in R/R AML with 89 subjects, and expects a comprehensive Part A data readout in Q1 2027.Material DetailsContext by AI AnalystThis is a mid-stage operational milestone in a pivotal Phase 2/3 program, c…